Kinases as potential targets for treatment of pulmonary hypertension and right ventricular dysfunction. (4th February 2020)

• Record Type: Journal Article
• Authors: Weiss, Astrid; Boehm, Mario; Egemnazarov, Bakytbek; Grimminger, Friedrich; Savai Pullamsetti, Soni; Kwapiszewska, Grazyna; Schermuly, Ralph T.
• Is Part Of: British journal of pharmacology. Volume 178:Number 1(2021)
• Page Start: 31
• Page End: 53
• Publication Date: 2020-02-04
• Subjects: Pharmacology -- Periodicals; Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1111/bph.14919
• Languages: English
• ISSNs: 0007-1188

Abstract

Abstract : Pulmonary hypertension (PH) is a progressive pulmonary vasculopathy that causes chronic right ventricular pressure overload and often leads to right ventricular failure. Various kinase inhibitors have been studied in the setting of PH and either improved or worsened the disease, highlighting the importance of understanding the specific role of the respective kinases in a spatiotemporal cellular context. In this review, we will summarize the knowledge on the role of kinases in PH and focus on druggable targets for which certain criteria are met: (a) deregulation of the kinase in PH; (b) small‐molecule inhibitors are available (e.g. from the oncology field); (c) preclinical studies have shown their efficacy in PH models; and (d) when available, therapeutic exploitation in human PH has been initiated. Along this line, clinical considerations such as personalized medicine approaches to predict therapy response and adverse side events such as cardiotoxicity together with their clinical management are discussed. LINKED ARTICLES: This article is part of a themed issue on Risk factors, comorbidities, and comedications in cardioprotection. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v178.1/issuetoc